Indicators
Indicators
Value
Direction
MACD(12,26,9)
-1.388
Neutral
RSI(14)
29.649
Sell
STOCH(KDJ)(9,3,3)
23.220
Neutral
ATR(14)
1.880
Low Volatility
CCI(14)
-368.698
Oversold
Williams %R
83.965
Oversold
TRIX(12,20)
0.161
Sell
StochRSI(14)
0.000
Sell
Search
Monte Rosa Therapeutics Inc
GLUEAdd to Watchlist
16.520USD
-6.160-27.16%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.40BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-27.16%
5 Days
-27.48%
1 Month
-31.76%
6 Months
-20.88%
Year to Date
+5.36%
1 Year
+244.89%
Key Figures
15.470Open
16.850High
7.47MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
8.86%Turnover Ratio
22.680Prev. Close
14.870Low
88.93MTurnover
LossP/E Static
2.67P/B
0.00%Div Yield TTM
-23.02%ROA
25.77052wk High
2.91Volume Ratio
-72.70MNet Profit
84.32MShares
-1.4812EPS TTM
1.61Beta
-32.62%ROE
3.90052wk Low
8.73%Amplitude
100.00%Gross Margin
1.40BMarket Cap
-0.58Reward/Risk
4.25%Risk Rate
TradingKey Stock Score of Monte Rosa Therapeutics Inc
Currency: USD Updated: 2026-07-31Key Insights
Monte Rosa Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 54 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 35.60.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Monte Rosa Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Monte Rosa Therapeutics Inc Highlights
StrengthsRisks
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Undervalued
The company’s latest PE is -11.15, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 72.05M shares, decreasing 2.39% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 54.25K shares of this stock.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
33.600
Target Price
+103.39%
Upside Space
Monte Rosa Therapeutics Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
9
analysts
Buy
Current Rating
33.600
Target Price
+103.39%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Monte Rosa Therapeutics Inc
GLUE
9
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
21.072
Sell
MA10
22.207
Sell
MA20
22.896
Sell
MA50
20.781
Sell
MA100
19.323
Sell
MA200
18.160
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Monte Rosa Therapeutics Inc Info
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Ticker SymbolGLUE
CompanyMonte Rosa Therapeutics Inc
CEOWarmuth (Markus)
Websitehttps://www.monterosatx.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-2.51%
+0.32%
-1.45%
-0.92%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
-0.90%
+1.30%
-2.15%Popular Instruments
52785.200
+407.200 (+0.78%)
28548.500
+387.600 (+1.38%)
7537.100
+62.000 (+0.83%)
14665.000
-84.000 (-0.57%)
63678.000
+826.000 (+1.31%)
6408.700
+43.300 (+0.68%)
78.830
-7.104 (-8.27%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4069.400
+27.970 (+0.69%)
FAQs
What is the current price of Monte Rosa Therapeutics Inc (GLUE)?
The current price of Monte Rosa Therapeutics Inc (GLUE) is 16.52.
What is the symbol of Monte Rosa Therapeutics Inc?
The ticker symbol of Monte Rosa Therapeutics Inc is GLUE.
What is the 52-week high of Monte Rosa Therapeutics Inc?
The 52-week high of Monte Rosa Therapeutics Inc is 25.77.
What is the 52-week low of Monte Rosa Therapeutics Inc?
The 52-week low of Monte Rosa Therapeutics Inc is 3.90.
What is the market capitalization of Monte Rosa Therapeutics Inc?
The market capitalization of Monte Rosa Therapeutics Inc is 1.40B.
Is Monte Rosa Therapeutics Inc (GLUE) currently rated as Buy, Hold, or Sell?
According to analysts, Monte Rosa Therapeutics Inc (GLUE) has an overall rating of Buy, with a price target of 33.60.
What is the Earnings Per Share (EPS TTM) of Monte Rosa Therapeutics Inc (GLUE)?
The Earnings Per Share (EPS TTM) of Monte Rosa Therapeutics Inc (GLUE) is -0.46.